Zabilugene almadenorepvec

N/A

Report date: 2025/05/29 14:08:07

Base Information

Drug NameZabilugene almadenorepvec
Drug Alias NameGenetically modified human adenovirus encoding human PH20 hyaluronidaseVCN-01
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionCell death stimulantsHyaluronic acid modulators
TargetsHyaluronic acid
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVCN Biosciences SL
China Registration ClassN/A

Develop Information

Active CompaniesTheriva Biologics SLTheriva Biologics IncUniversity Of Pennsylvania
Inactive CompaniesInstitut Català D'Oncologia
Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsRetinoblastoma
Inactive IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A